Lipocine News

Lipocine 1Q Rev $7.62M >LPCN

Lipocine 1Q Rev $7.62M >LPCN

Dow JonesMay 9 08:05 ET

Earnings Flash (LPCN) LIPOCINE Reports Q1 Revenue $7.6M

08:01 AM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (LPCN) LIPOCINE Reports Q1 Revenue $7.6M

MT NewswiresMay 9 08:01 ET

Express News | Lipocine Q1 Net Income USD 3.5 Million

ReutersMay 9 08:00 ET

Express News | Lipocine Q1 EPS USD 0.66

ReutersMay 9 08:00 ET

Lipocine | 10-Q: Quarterly report

Futu NewsMay 9 06:12 ET · Announcements

Express News | Lipocine Inc: Qtrly Shr $0.66

ReutersMay 9 06:07 ET

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

SALT LAKE CITY, May 9, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024 and provided a corpo

LipocineMay 9 00:00 ET

Lipocine Announces Late Breaking Oral Presentation Of Data From The Phase 2 Study Of LPCN 1148 At EASL Congress 2024

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European Associat

BenzingaMay 8 08:04 ET

Express News | Lipocine Announces Late Breaking Oral Presentation of Data From the Phase 2 Study of Lpcn 1148 at Easl Congress 2024

ReutersMay 8 08:00 ET

Lipocine Announces Late Breaking Oral Presentation of Data From the Phase 2 Study of LPCN 1148 at EASL Congress 2024

SALT LAKE CITY, May 8, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaki

LipocineMay 8 00:00 ET

Express News | Lipocine Announces Completion Of Dosing In Pivotal Study Of Postpartum Depression Candidate, LPCN 1154

BenzingaMay 1 08:15 ET

Express News | Lipocine: Confirmed With FDA Acceptance of Proposal for Nda Filing Enabled by Pivotal Pk Study Comparing Exposure of Lpcn 1154 With IV Infusion of Brexanolone

ReutersMay 1 08:02 ET

Express News | Lipocine Inc: Topline Results Anticipated Late in 2Q 2024

ReutersMay 1 08:01 ET

Express News | Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, Lpcn 1154

ReutersMay 1 08:00 ET

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

Pivotal study design aligned with FDA on streamlined pathway to NDA submission goal in 2024Topline results anticipated late in 2Q 2024SALT LAKE CITY, May 1, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ:

LipocineMay 1 00:00 ET

Lipocine Initiates New ATM Offering, Ends Previous Agreement

TipRanksApr 26 17:33 ET

Express News | Lipocine Inc - on April 24 Provided Notice to Cantor of Its Election to Terminate the Controlled Equity Offeringsm Sales Agreement

ReutersApr 26 17:23 ET

Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial

Lipocine (LPCN) said Thursday that a phase 2 trial of LPCN 2401 showed improved body composition in participants with obesity. LPCN 2401 demonstrated increased lean mass by 4.4% and reduced fat mass b

MT NewswiresApr 12 13:35 ET

12 Health Care Stocks Moving In Thursday's Pre-Market Session

GainersEliem Therapeutics (NASDAQ:ELYM) stock moved upwards by 51.6% to $4.05 during Thursday's pre-market session. The market value of their outstanding shares is at $112.2 million. Rallybio (NASDAQ:

BenzingaApr 11 08:10 ET

Lipocine Reports Positive Results From Obesity Treatment Trial

InvestingApr 11 07:54 ET